TORONTO, ONTARIO--(Marketwired - April 24, 2013) - Biologix Hair Inc. (OTCBB:BLGX) (OTCQB:BLGX) is pleased to announce the appointment of Arthur G. Handal M.D., F.A.C.S. to the Company's Medical Advisory Board.
Certified by the American Board of Plastic Surgery, Dr. Arthur G. Handal's interest in plastic/cosmetic surgery began at the Chicago/UHS Medical School and became focused during his residency at State University New York. Handal gained early acceptance into the SUNY/Kings County Medical Center and upon completion of his residency, he continued surgical training with prestigious fellowships in aesthetic surgery in association with the University of Miami and hand surgery at Hartford Hospital in Connecticut. For more than 20 years, Dr. Handal has dedicated his practice to aesthetic plastic surgery.
Dr. Handal's private, professional Sanctuary Surgical Center, affiliated with the Boca Raton Community Hospital offers surgery and pre- and post-operative care in a state of the art, fully licensed facility accredited at the highest level as an ambulatory surgical center, and offers a full range of aesthetic services.
He is a member of the American Society of Plastic Surgeons, American Society for Aesthetic Plastic Surgery, American College of Surgeons, Southeastern Society of Plastic and Reconstructive Surgeons, Palm Beach County Society of Plastic and Reconstructive Surgery Florida Medical Association, Palm Beach County Medical Society and the American Society of Laser Medicine and Surgery. Dr. Handal offers cutting-edge techniques and innovations to his patients, developed through attending the major professional meetings several times a year.
Dr. Arthur Handal commented, "I am pleased to become part of the Biologix Hair Inc. team by serving on its Medical Advisory Board. The ongoing R&D efforts being undertaken by Biologix with the Beijing Institute of Technology and level of professionalism with which the Company is working toward application for regulatory agency approval is a smart strategy. I am particularly impressed with the attention being paid to developing an international distribution channel of licensed clinicians and medical practitioners in advance of FDA approval thereby readying Biologix to penetrate the global market potential for its Biologix Hair Therapy System™."
Ron Holland, Biologix Hair Inc. CEO and Director, welcomed Dr. Handal, commenting: "Dr. Handal's experience and knowledge are of vast benefit to Biologix and we are grateful he's consented to serve on the Biologix Medical Advisory Board. As we further build out the global network of clinicians who wish to become Certified Biologix Hair Therapists™ as well as maintain our ongoing R&D efforts, the advice offered by members of our Medical Advisory Board will be integral to our continuing development. We welcome Dr. Handal to the Biologix team."
About Biologix Hair Inc. and Biologix Hair Science Ltd.
Biologix Hair Inc. (Biologix Hair), together with its wholly owned biotechnology subsidiary, Biologix Hair Science Ltd. ™ (BHS), is focused on realizing the full market potential for its patent-pending hair loss prevention and regeneration treatment - the Biologix Hair Therapy System™ - and its demonstrated ability to prevent and reverse the effects of alopecia, which plagues hundreds of millions worldwide.
Between mid-2004 and mid-2012, more than 30,000 pre-clinical-trial treatments of Biologix Revive - the essence of the Biologix Hair Therapy System™ - were administered to 5,000-plus patients in South America suffering with varying degrees of alopecia, as well as people seeking preventive treatment. The participating treatment clinicians subjectively observed and reported that virtually 100% of preventive care clients continued to retain their healthy hair and an estimated 80-85% of the males and 90-plus% of the females treated for hair regeneration experienced significant regrowth of their own natural hair. And among alopecia areata patients, virtually total hair regrowth was observed in 100% of the cases. To date, no negative side effects have been reported.
BHS is currently focused on obtaining FDA approval for its breakthrough hair loss prevention and regeneration therapy and has initiated a research and development program with one of the world's leading medical research universities, the Beijing Institute of Technology (BIT). The R&D program, expected to take approximately twelve months to complete, is an important final step before formal clinical trials and the FDA approval process begins.
Additionally, on May 11, 2012, Venable LLP, the Washington-based law firm overseeing the worldwide IP and regulatory approval processes on behalf of BHS, filed a Patent Cooperation Treaty (PCT) application on behalf of BHS for Biologix Revive in Geneva, Switzerland. The PCT is an international treaty, administered by the World Intellectual Property Organization (WIPO), to which 144 countries have as of now contracted, including Canada and the United States.
Biologix management is determined to be in a ready position to capitalize on the high-margin sales potential of the Biologix Hair Therapy System™, if and when FDA and other major market approvals are forthcoming.
As BHS advances the regulatory approval process, Biologix Hair, together with wholly owned subsidiary companies operated by BHS, are rapidly developing a global distribution network of licensed clinicians and medical practitioners seeking to become Certified Biologix Hair Therapists™ and secure exclusive territorial purchasing and treatment rights for the Biologix Hair Therapy System™.
Biologix Hair has decided not to risk creating any potential regulatory conflicts by offering treatment outside the United States and other major high-product-margin markets until FDA approval has been granted. Therefore, the Biologix Hair Therapy System™ is not yet available other than to the 5,000+ patients who participated in the pre-clinical-trials conducted in South America.
To learn more about Clinician Licensing opportunities, Click Here or call toll free +1 855.737.0333 or +1 647.344.5900.
Disclaimer
This announcement is not an offer to sell any Biologix Hair Inc. ("Biologix") securities. Offers for any given security are made only through applicable offering circulars and related documents filed with the SEC pursuant to the Securities Act of 1933 or the Securities Exchange Act of 1934. Certain statements contained herein and subsequent oral statements made by and on behalf of Biologix may contain "forward-looking statements". Such forward-looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and includes, without limitation, the development of treatment centers and approval from regulatory authorities as well as the ability for Biologix to obtain adequate financing to meet its business objectives. Forward-looking statements express our expectations or predictions of future events or results. They are not guarantees and are subject to many risks and uncertainties. There are a number of factors beyond our control that could cause actual events or results to be significantly different from those described in the forward-looking statements. Any or all of our forward-looking statements in this report or in any other public statements we make may turn out to be wrong. We undertake no obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise. In Canada, Europe and the United States, the Biologix treatment is not approved for use by Health Canada, EMA or the FDA. The company makes no representations that it will receive Health Canada, EMA or FDA approvals.
test123 kjk
